Your browser doesn't support javascript.
loading
Author Correction: Tryptophan depletion results in tryptophan-to-phenylalanine substitutants.
Pataskar, Abhijeet; Champagne, Julien; Nagel, Remco; Kenski, Juliana; Laos, Maarja; Michaux, Justine; Pak, Hui Song; Bleijerveld, Onno B; Mordente, Kelly; Navarro, Jasmine Montenegro; Blommaert, Naomi; Nielsen, Morten M; Lovecchio, Domenica; Stone, Everett; Georgiou, George; de Gooijer, Mark C; van Tellingen, Olaf; Altelaar, Maarten; Joosten, Robbie P; Perrakis, Anastassis; Olweus, Johanna; Bassani-Sternberg, Michal; Peeper, Daniel S; Agami, Reuven.
Afiliação
  • Pataskar A; Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Champagne J; Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Nagel R; Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Kenski J; Division of Molecular Oncology and Immunology, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Laos M; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
  • Michaux J; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Pak HS; Lausanne Branch, Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
  • Bleijerveld OB; Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  • Mordente K; Lausanne Branch, Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
  • Navarro JM; Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  • Blommaert N; NKI Proteomics facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Nielsen MM; Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Lovecchio D; Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Stone E; Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Georgiou G; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
  • de Gooijer MC; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • van Tellingen O; Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Altelaar M; Department of Molecular Biosciences, University of Texas, Austin, TX, USA.
  • Joosten RP; Department of Molecular Biosciences, University of Texas, Austin, TX, USA.
  • Perrakis A; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Olweus J; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Bassani-Sternberg M; NKI Proteomics facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Peeper DS; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, Utrecht, The Netherlands.
  • Agami R; Division of Biochemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Nature ; 608(7922): E20, 2022 Aug.
Article em En | MEDLINE | ID: mdl-35840685
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article